4.1.1.53 Ataxia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33889127&form=6&db=m Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials. therapeutic application,unassigned 1,0 4.1.1.53 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24467211&form=6&db=m Glycine decarboxylase is an unusual amino acid decarboxylase involved in tumorigenesis. causal interaction,unassigned 3,0 4.1.1.53 Carcinoid Tumor http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13928592&form=6&db=m [Amino acid decarboxylase in pheochromocytoma and carcinoid tissue.] causal interaction,ongoing research,unassigned 1,2,0 4.1.1.53 Cerebral Palsy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1078720&form=6&db=m Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486. diagnostic usage,therapeutic application,unassigned 3,1,0 4.1.1.53 Dyskinesias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=159153&form=6&db=m [Serum dopamine-beta-hydroxylase, glutamic acid decarboxylase and 1-aromatic amino acid decarboxylase in involuntary movement disorders (author's transl)] diagnostic usage,unassigned 1,0 4.1.1.53 Dystonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25597765&form=6&db=m Syndromic intellectual disability: A new phenotype caused by an aromatic amino acid decarboxylase gene (DDC) variant. causal interaction,unassigned 3,0 4.1.1.53 Dystonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33889127&form=6&db=m Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials. therapeutic application,unassigned 1,0 4.1.1.53 Huntington Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33889127&form=6&db=m Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials. therapeutic application,unassigned 1,0 4.1.1.53 Hypotension, Orthostatic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18368303&form=6&db=m L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience. therapeutic application,unassigned 1,0 4.1.1.53 Hypothyroidism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7389157&form=6&db=m TSH and prolactin stimulation by the decarboxylase inhibitor benserazide in primary hypothyroidism. diagnostic usage,ongoing research,therapeutic application,unassigned 3,1,2,0 4.1.1.53 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8806108&form=6&db=m Expression in human lung cancer cell lines of genes of prohormone processing and the neuroendocrine phenotype. diagnostic usage,ongoing research,unassigned 3,1,0 4.1.1.53 Migraine Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16200390&form=6&db=m A genetic analysis of serotonergic biosynthetic and metabolic enzymes in migraine using a DNA pooling approach. diagnostic usage,ongoing research,unassigned 3,4,0 4.1.1.53 Movement Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=159153&form=6&db=m [Serum dopamine-beta-hydroxylase, glutamic acid decarboxylase and 1-aromatic amino acid decarboxylase in involuntary movement disorders (author's transl)] diagnostic usage,unassigned 1,0 4.1.1.53 Movement Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33889127&form=6&db=m Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials. therapeutic application,unassigned 1,0 4.1.1.53 Multiple System Atrophy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33889127&form=6&db=m Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials. therapeutic application,unassigned 1,0 4.1.1.53 Muscle Hypotonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25597765&form=6&db=m Syndromic intellectual disability: A new phenotype caused by an aromatic amino acid decarboxylase gene (DDC) variant. causal interaction,unassigned 3,0 4.1.1.53 Myoclonus http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1078720&form=6&db=m Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486. diagnostic usage,therapeutic application,unassigned 3,1,0 4.1.1.53 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=4770333&form=6&db=m Fluorescence and electron microscopic histochemistry of endocrine-like cells in gastric mucosa and argyrophil tumor of Praomys (Mastomys) natalensis. Analysis of 5-hydroxytryptamine, histamine, Histidine decarboxylase, and aromatic amino acid decarboxylase. ongoing research,unassigned 2,0 4.1.1.53 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6661425&form=6&db=m Use of radiolabeled monofluoromethyl-Dopa to define the subunit structure of human L-Dopa decarboxylase. causal interaction,ongoing research,unassigned 1,2,0 4.1.1.53 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8806108&form=6&db=m Expression in human lung cancer cell lines of genes of prohormone processing and the neuroendocrine phenotype. diagnostic usage,ongoing research,unassigned 3,1,0 4.1.1.53 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23213196&form=6&db=m Characterization of neuroblastic tumors using 18F-FDOPA PET. causal interaction,unassigned 1,0 4.1.1.53 Neuroendocrine Tumors http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23213196&form=6&db=m Characterization of neuroblastic tumors using 18F-FDOPA PET. causal interaction,unassigned 1,0 4.1.1.53 Neuroendocrine Tumors http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34495420&form=6&db=m The effects of molar activity on [18F]FDOPA uptake in patients with neuroendocrine tumors. unassigned - 4.1.1.53 Neurologic Manifestations http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25597765&form=6&db=m Syndromic intellectual disability: A new phenotype caused by an aromatic amino acid decarboxylase gene (DDC) variant. causal interaction,unassigned 3,0 4.1.1.53 Paralysis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33889127&form=6&db=m Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials. therapeutic application,unassigned 1,0 4.1.1.53 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9372552&form=6&db=m Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment. causal interaction,therapeutic application,unassigned 1,4,0 4.1.1.53 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9403227&form=6&db=m Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. causal interaction,therapeutic application,unassigned 3,4,0 4.1.1.53 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26366963&form=6&db=m Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations. therapeutic application,unassigned 2,0 4.1.1.53 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31744341&form=6&db=m Cheminformatics and virtual screening studies of COMT inhibitors as potential Parkinson's disease therapeutics. causal interaction,therapeutic application,unassigned 3,4,0 4.1.1.53 Parkinson Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33889127&form=6&db=m Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials. therapeutic application,unassigned 1,0 4.1.1.53 phenylalanine decarboxylase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34244047&form=6&db=m Corrigendum to "Aromatic amino acid decarboxylase deficiency: Molecular and metabolic basis and therapeutic outlook" [Mol Genet Metab. 2019 May;127(1):12-22]. unassigned - 4.1.1.53 Pheochromocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=6661425&form=6&db=m Use of radiolabeled monofluoromethyl-Dopa to define the subunit structure of human L-Dopa decarboxylase. causal interaction,ongoing research,unassigned 1,2,0 4.1.1.53 Pheochromocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13928592&form=6&db=m [Amino acid decarboxylase in pheochromocytoma and carcinoid tissue.] causal interaction,ongoing research,unassigned 1,2,0 4.1.1.53 Small Cell Lung Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8806108&form=6&db=m Expression in human lung cancer cell lines of genes of prohormone processing and the neuroendocrine phenotype. diagnostic usage,ongoing research,unassigned 3,1,0 4.1.1.53 Supranuclear Palsy, Progressive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33889127&form=6&db=m Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials. therapeutic application,unassigned 1,0 4.1.1.53 Tremor http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1078720&form=6&db=m Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486. diagnostic usage,therapeutic application,unassigned 3,1,0 4.1.1.53 Tremor http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33889127&form=6&db=m Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials. therapeutic application,unassigned 1,0 4.1.1.53 tryptophan 5-monooxygenase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24553000&form=6&db=m Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters. causal interaction,unassigned 3,0